Why Baxter International Inc. (BAX) Is Soaring Despite Alzheimer’s Disappointment

Page 2 of 2

Conclusion

Pharmaceutical industry has been, and will always be, a speculative industry. In my opinion, risk averse investors with limited or no knowledge of the biotech industry should strictly stay away from it. With that said, I believe that Baxter International Inc. (NYSE:BAX) a good income growth stock to hold. Its pending acquisition of Gambro has also received regulatory clearance, and should add significant value.

Piyush Arora has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Momenta Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson and Momenta Pharmaceuticals.

The article Why Baxter Is Soaring Despite Alzheimer’s Disappointment originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2